Status: Not yet recruiting
SWITCH: Apixaban vs Vitamin K in HM3
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.
Participants needed: 460
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Columbia UniversityUpdated: Mar 13, 2026
Eligibility criteria
Participants will have HeartMate3 LVAD implanted > 3 months before enrollment [+4]
Participation in any other clinical investigation(s) involving a Mechanical Circ... [+7]